Targeted ACE inhibitors for the Treatment of Dilated Cardiomyopathy (DCM)

Dilated cardiomyopathy, a subtype of cardiomyopathies characterized by ventricular dilation, particularly of the left or both ventricles, coupled with systolic impairment, represents a heterogeneous condition distinct from valvular heart disorders, congenital cardiac anomalies, hypertensive cardiomyopathy, and acyanotic heart diseases. This article explores the varied categories of angiotensin-converting enzyme (ACE) inhibitors and their precise molecular targets. As a relatively uncommon disease entity, dilated cardiomyopathy lacks a definitive pharmacological cure and is managed primarily through medical therapy or surgical interventions. Emerging therapeutic modalities, such as left ventricular assist device (LVAD) support, have been introduced, yet the majority of these treatments necessitate careful consideration due to their specific indications and potential implications.